Literature DB >> 32907925

Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation.

Luca Cassetta1, Kirsten Bruderek2, Joanna Skrzeczynska-Moncznik3, Oktawia Osiecka3, Xiaoying Hu4,5, Ida Marie Rundgren6, Ang Lin7,8, Kim Santegoets9, Utku Horzum10, Ana Godinho-Santos11, Gennadiy Zelinskyy12, Thalia Garcia-Tellez13, Sunčica Bjelica14, Bartłomiej Taciak15,16, Astrid Olsnes Kittang17, Benedikt Höing2, Stephan Lang2, Michael Dixon18, Verena Müller4,5, Jochen Sven Utikal5,19, Derya Karakoç20,21, Kerim Bora Yilmaz20,22, Emilia Górka15,16, Lubomir Bodnar23,24, Olympia Evdoxia Anastasiou12, Christine Bourgeois25, Robert Badura11,26, Monika Kapinska-Mrowiecka27, Mirjana Gotic28, Mark Ter Laan29, Esther Kers-Rebel9, Magdalena Król15,16, Juan Francisco Santibañez14,30, Michaela Müller-Trutwin13, Ulf Dittmer12, Ana Espada de Sousa11, Güneş Esendağlı10,20, Gosse Adema31, Karin Loré7,8, Elisabeth Ersvær6, Viktor Umansky5,19, Jeffrey W Pollard1, Joanna Cichy3, Sven Brandau32,33.   

Abstract

BACKGROUND: Myeloid-derived suppressor cells (MDSC) are a functional myeloid cell subset that includes myeloid cells with immune suppressive properties. The presence of MDSC has been reported in the peripheral blood of patients with several malignant and non-malignant diseases. So far, direct comparison of MDSC across different diseases and Centers is hindered by technical pitfalls and a lack of standardized methodology. To overcome this issue, we formed a network through the COST Action Mye-EUNITER (www.mye-euniter.eu) with the goal to standardize and facilitate the comparative analysis of human circulating MDSC in cancer, inflammation and infection. In this manuscript, we present the results of the multicenter study Mye-EUNITER MDSC Monitoring Initiative, that involved 13 laboratories and compared circulating MDSC subsets across multiple diseases, using a common protocol for the isolation, identification and characterization of these cells.
METHODS: We developed, tested, executed and optimized a standard operating procedure for the isolation and immunophenotyping of MDSC using blood from healthy donors. We applied this procedure to the blood of almost 400 patients and controls with different solid tumors and non-malignant diseases. The latter included viral infections such as HIV and hepatitis B virus, but also psoriasis and cardiovascular disorders.
RESULTS: We observed that the frequency of MDSC in healthy donors varied substantially between centers and was influenced by technical aspects such as the anticoagulant and separation method used. Expansion of polymorphonuclear (PMN)-MDSC exceeded the expansion of monocytic MDSC (M-MDSC) in five out of six solid tumors. PMN-MDSC expansion was more pronounced in cancer compared with infection and inflammation. Programmed death-ligand 1 was primarily expressed in M-MDSC and e-MDSC and was not upregulated as a consequence of disease. LOX-1 expression was confined to PMN-MDSC.
CONCLUSIONS: This study provides improved technical protocols and workflows for the multi-center analysis of circulating human MDSC subsets. Application of these workflows revealed a predominant expansion of PMN-MDSC in solid tumors that exceeds expansion in chronic infection and inflammation. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  biomarkers; cellular; head and neck neoplasms; immunity; immunoassay; myeloid-derived suppressor cells; tumor

Mesh:

Year:  2020        PMID: 32907925      PMCID: PMC7481096          DOI: 10.1136/jitc-2020-001223

Source DB:  PubMed          Journal:  J Immunother Cancer        ISSN: 2051-1426            Impact factor:   13.751


  29 in total

1.  Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy.

Authors:  Sourina Pal; Madhuparna Nandi; Debangana Dey; Bidhan Chandra Chakraborty; Achintya Shil; Saurabh Ghosh; Soma Banerjee; Amal Santra; S K Mahiuddin Ahammed; Abhijit Chowdhury; Simanti Datta
Journal:  Aliment Pharmacol Ther       Date:  2019-04-15       Impact factor: 8.171

Review 2.  Myeloid-Derived Suppressor Cells.

Authors:  Dmitry I Gabrilovich
Journal:  Cancer Immunol Res       Date:  2017-01       Impact factor: 11.151

3.  Myeloid-Derived Suppressor Cells Associated With Disease Progression in Primary HIV Infection: PD-L1 Blockade Attenuates Inhibition.

Authors:  Zi-Ning Zhang; Nan Yi; Tong-Wei Zhang; Le-Le Zhang; Xian Wu; Mei Liu; Ya-Jing Fu; Si-Jia He; Yong-Jun Jiang; Hai-Bo Ding; Zhen-Xing Chu; Hong Shang
Journal:  J Acquir Immune Defic Syndr       Date:  2017-10-01       Impact factor: 3.731

Review 4.  History of myeloid-derived suppressor cells.

Authors:  James E Talmadge; Dmitry I Gabrilovich
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

Review 5.  Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients.

Authors:  Jingwei Jiang; Weijian Guo; Xiaohua Liang
Journal:  Hum Immunol       Date:  2014-10-07       Impact factor: 2.850

6.  Multidimensional imaging provides evidence for down-regulation of T cell effector function by MDSC in human cancer tissue.

Authors:  Yu Si; Simon F Merz; Philipp Jansen; Baoxiao Wang; Kirsten Bruderek; Petra Altenhoff; Stefan Mattheis; Stephan Lang; Matthias Gunzer; Joachim Klode; Anthony Squire; Sven Brandau
Journal:  Sci Immunol       Date:  2019-10-18

Review 7.  Myeloid-derived suppressor cells as regulators of the immune system.

Authors:  Dmitry I Gabrilovich; Srinivas Nagaraj
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

Review 8.  Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.

Authors:  Viktor Fleming; Xiaoying Hu; Rebekka Weber; Vasyl Nagibin; Christopher Groth; Peter Altevogt; Jochen Utikal; Viktor Umansky
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

Review 9.  Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates.

Authors:  Luca Cassetta; Espen S Baekkevold; Sven Brandau; Anna Bujko; Marco A Cassatella; Anca Dorhoi; Carsten Krieg; Ang Lin; Karin Loré; Olivia Marini; Jeffrey W Pollard; Mikael Roussel; Patrizia Scapini; Viktor Umansky; Gosse J Adema
Journal:  Cancer Immunol Immunother       Date:  2019-01-25       Impact factor: 6.968

Review 10.  PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.

Authors:  Yilun Wu; Weiyu Chen; Zhi Ping Xu; Wenyi Gu
Journal:  Front Immunol       Date:  2019-08-27       Impact factor: 7.561

View more
  37 in total

1.  Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity.

Authors:  Sara Falck-Jones; Sindhu Vangeti; Meng Yu; Ryan Falck-Jones; Alberto Cagigi; Isabella Badolati; Björn Österberg; Maximilian Julius Lautenbach; Eric Åhlberg; Ang Lin; Rico Lepzien; Inga Szurgot; Klara Lenart; Fredrika Hellgren; Holden Maecker; Jörgen Sälde; Jan Albert; Niclas Johansson; Max Bell; Karin Loré; Anna Färnert; Anna Smed-Sörensen
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

2.  Decreased neutrophil-mediated bacterial killing in COVID-19 patients.

Authors:  Masoumeh Nomani; Mohammad Varahram; Payam Tabarsi; Seyed MohammadReza Hashemian; Hamidreza Jamaati; Majid Malekmohammad; Mona Ghazi; Ian M Adcock; Esmaeil Mortaz
Journal:  Scand J Immunol       Date:  2021-06-11       Impact factor: 3.889

3.  Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma.

Authors:  Daniel J Gross; Navin K Chintala; Raj G Vaghjiani; Rachel Grosser; Kay See Tan; Xiaoyu Li; Jennie Choe; Yan Li; Rania G Aly; Katsura Emoto; Hua Zheng; Joseph Dux; Waseem Cheema; Matthew J Bott; William D Travis; James M Isbell; Bob T Li; David R Jones; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2021-10-08       Impact factor: 15.609

4.  c-Rel-dependent monocytes are potent immune suppressor cells in cancer.

Authors:  Ting Li; Mayassa J Bou-Dargham; Norman Fultang; Xinyuan Li; Warren S Pear; Honghong Sun; Youhai H Chen
Journal:  J Leukoc Biol       Date:  2022-06-13       Impact factor: 6.011

5.  Depleting Ly6G Positive Myeloid Cells Reduces Pancreatic Cancer-Induced Skeletal Muscle Atrophy.

Authors:  Michael R Deyhle; Chandler S Callaway; Daria Neyroud; Andrew C D'Lugos; Sarah M Judge; Andrew R Judge
Journal:  Cells       Date:  2022-06-10       Impact factor: 7.666

Review 6.  Monocyte Regulation in Homeostasis and Malignancy.

Authors:  Amy Robinson; Claudia Z Han; Christopher K Glass; Jeffrey W Pollard
Journal:  Trends Immunol       Date:  2021-01-11       Impact factor: 16.687

Review 7.  Developmental pathways of myeloid-derived suppressor cells in neoplasia.

Authors:  Scott I Abrams
Journal:  Cell Immunol       Date:  2020-12-16       Impact factor: 4.868

8.  Healthy myeloid-derived suppressor cells express the surface ectoenzyme Vanin-2 (VNN2).

Authors:  David C Soler; Amber Kerstetter-Fogle; Andrew B Young; Pat Rayman; James H Finke; Sarah M Debanne; Kevin D Cooper; Jill Barnholtz-Sloan; Andrew E Sloan; Thomas S McCormick
Journal:  Mol Immunol       Date:  2021-12-23       Impact factor: 4.407

Review 9.  Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?

Authors:  Fabrice Tolle; Viktor Umansky; Jochen Utikal; Stephanie Kreis; Sabrina Bréchard
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

Review 10.  Myeloid-derived suppressor cells in COVID-19: A review.

Authors:  Yuliya V Perfilyeva; Yekaterina O Ostapchuk; Raikhan Tleulieva; Aykin Kali; Nurshat Abdolla; Vladimir K Krasnoshtanov; Anastassiya V Perfilyeva; Nikolai N Belyaev
Journal:  Clin Immunol       Date:  2022-04-27       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.